Sensyne signs SRA with Royal Wolverhampton NHS Trust

Sensyne Health CEO Paul Drayson
Paul Drayson, CEO, Sensyne Health

Sensyne Health plc is continuing to roll out its clinical AI research partnerships with NHS trusts after signing a five-year Strategic Research Agreement (SRA) with The Royal Wolverhampton NHS Trust (RWT).

Under the deal, which covers 700,000 unique patient records from a patient population of approximately 470,000, the RWT will receive 1,428,571 ordinary shares in Sensyne Health plc representing 0.9% of the company’s existing issued share capital. In common with other SRAs, it will also receive investment from Sensyne of up to £250,000 per year over the five-year term of the contract for investment in research related IT. In addition, it will receive royalties on revenue generated from the research which will be reinvested in patient care.

Sensyne has signed nine SRAs with NHS trusts to date, along with a data access agreement signed with NHS Greater Glasgow and Clyde. This brings the total share ownership in Sensyne held by NHS trusts to 12.6%.

Sensyne Health CEO Lord (Paul) Drayson said: ‘I would like to welcome The Royal Wolverhampton NHS Trust as a new SRA partner and look forward to working with them.  The SRA continues Sensyne’s momentum in expanding its anonymised patient data set and deepening the diversity of the therapeutic areas within it.  This in turn helps provide Sensyne with the critical mass of data to improve patient care and accelerate medical research.’